Processa Pharmaceuticals, Inc. Share-based Goods and Nonemployee Services Transaction, Cash Flow Effects (Deprecated 2013-01-31)
Processa Pharmaceuticals, Inc. (PCSA) reported Share-based Goods and Nonemployee Services Transaction, Cash Flow Effects (Deprecated 2013-01-31) of $25.50 thousand for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-15.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionCashFlowEffects · last filed 2015-05-15
- Processa Pharmaceuticals, Inc. share-based goods and nonemployee services transaction, cash flow effects (deprecated 2013-01-31) for the quarter ending 2015-03-31 was $25.50K.
- Processa Pharmaceuticals, Inc. share-based goods and nonemployee services transaction, cash flow effects (deprecated 2013-01-31) for the quarter ending 2013-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. share-based goods and nonemployee services transaction, cash flow effects (deprecated 2013-01-31) for the quarter ending 2013-09-30 was $0.00.
| Period end | Share-based Goods and Nonemployee Services Transaction, Cash Flow Effects (Deprecated 2013-01-31) 3 month | Share-based Goods and Nonemployee Services Transaction, Cash Flow Effects (Deprecated 2013-01-31) 6 month | Share-based Goods and Nonemployee Services Transaction, Cash Flow Effects (Deprecated 2013-01-31) 27 month | Share-based Goods and Nonemployee Services Transaction, Cash Flow Effects (Deprecated 2013-01-31) 30 month | Share-based Goods and Nonemployee Services Transaction, Cash Flow Effects (Deprecated 2013-01-31) 33 month |
|---|---|---|---|---|---|
| 2015-03-31 | $25.50K 10-Q · filed 2015-05-15 | ||||
| 2013-12-31 | $0.00 derived: 10-K 33 month − 10-Q 30 month · filed 2014-03-27 | $0.00 derived: sum of 2 quarters · filed 2014-03-27 | $1.69K 10-K · filed 2014-03-27 | ||
| 2013-09-30 | $0.00 derived: 10-Q 30 month − 10-Q/A 27 month · filed 2013-11-08 | $1.69K 10-Q · filed 2013-11-08 | |||
| 2013-06-30 | $1.69K 10-Q/A · filed 2013-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |